NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $6.93 +0.44 (+6.78%) Closing price 04:00 PM EasternExtended Trading$6.83 -0.10 (-1.44%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About SOPHiA GENETICS Stock (NASDAQ:SOPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$6.39▼$6.9750-Day Range$6.49▼$8.9252-Week Range$3.75▼$8.98Volume639,325 shsAverage Volume323,120 shsMarket Capitalization$581.36 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions. The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine. The platform is intended to help laboratories and clinical teams standardize workflows, interpret test results and share insights across institutions. Founded in 2011 and headquartered in Switzerland, SOPHiA GENETICS serves hospitals, laboratories, academic institutions and pharmaceutical companies in multiple international markets. Its technology is used to support clinical diagnostics, translational research and drug development, with an emphasis on enabling collaboration and the broader adoption of data-driven healthcare.AI Generated. May Contain Errors. Read More SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreSOPH MarketRank™: 3.07431984074 of 5 starsSOPHiA GENETICS scored higher than 61% of companies evaluated by MarketBeat, and ranked 288th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSOPHiA GENETICS has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSOPHiA GENETICS has a consensus price target of $10.00, representing about 44.3% upside from its current price of $6.93.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 3 research reports in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.77) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 10.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SOPHiA GENETICS's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.40% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 4.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentSOPHiA GENETICS has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for SOPHiA GENETICS this week, compared to 5 articles on an average week.MarketBeat Follows3 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,256,756.00 in company stock.Percentage Held by Insiders4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by Institutions31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SOPH Stock News HeadlinesSOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026October 20 at 8:00 AM | prnewswire.comSOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Zhenyu Xu Sells 4,000 SharesOctober 15, 2026 | insidertrades.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 20 at 1:00 AM | Weiss Ratings (Ad)SOPHiA GENETICS (NASDAQ:SOPH) Given "Buy" Rating at HC WainwrightOctober 12, 2026 | americanbankingnews.comSophia Genetics, Myriad Genetics Collaborate on Prostate Cancer BiomarkerOctober 10, 2026 | finance.yahoo.comSOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Jurgi Camblong Sells 40,172 SharesOctober 9, 2026 | americanbankingnews.comSOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score TechnologyOctober 8, 2026 | rttnews.comSOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider George Cardoza Sells 1,592 SharesOctober 8, 2026 | insidertrades.comSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $4.67 on January 1st, 2026. Since then, SOPH stock has increased by 48.4% and is now trading at $6.93. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) released its earnings results on Wednesday, August, 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05. The company earned $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative trailing twelve-month return on equity of 132.47%. Read the conference call transcript. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering (IPO) on Wednesday, July 21st 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Caribou Biosciences (CRBU), Micron Technology (MU), Advanced Micro Devices (AMD), Marvell Technology (MRVL) and Tesla (TSLA). Company Calendar Last Earnings8/05/2026Today10/20/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SOPH's financial health is in the Green zone, according to TradeSmith. SOPH has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees415Year Founded2011Price Target and Rating Average Price Target for SOPHiA GENETICS$10.00 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+44.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79 million Net Margins-93.86% Pretax Margin-93.19% Return on Equity-132.47% Return on Assets-45.97% Debt Debt-to-Equity Ratio0.58 Current Ratio2.69 Quick Ratio2.55 Sales & Book Value Annual Sales$77.27 million Price / Sales7.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book10.04Miscellaneous Outstanding Shares83,890,000Free Float79,801,000Market Cap$581.36 million OptionableOptionable Beta0.95 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:SOPH) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
